Evidence map›Paper›PMID 42332324›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026

Getting fairer over time? Assessing changes in health technology funding processes using the accountability for reasonableness (A4R) framework.

Jing Jing Li, Marcus Sellars, Joanna Coast, Stacy M Carter, Kirsten Howard, Duncan Mortimer, Emily Lancsar

Abstract read
PubMed Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jing Jing LiCentre for Health Economics, Monash Business School, Monash University, Level 5, Building H, Caulfield Campus, Melbourne, VIC, 3145, Australia. jingjing.li@monash.edu.ORCID http://orcid.org/0009-0001-7993-7490
Marcus SellarsCentre for Quality and Patient Safety Research (QPS), Institute of Health Transformation, School of Nursing and Midwifery, Deakin University, Burwood, Australia.ORCID http://orcid.org/0000-0002-8299-0313
Joanna CoastHealth Economics & Health Policy (HEHP@Bristol), Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-3537-5166
Stacy M CarterAustralian Centre for Health Engagement, Evidence and Values (ACHEEV), School of Health and Society, University of Wollongong, Wollongong, Australia.ORCID http://orcid.org/0000-0003-2617-8694
Kirsten HowardThe Leeder Centre for Health Policy, Economics and Data, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-0918-7540
Duncan MortimerCentre for Health Economics, Monash Business School, Monash University, Level 5, Building H, Caulfield Campus, Melbourne, VIC, 3145, Australia.ORCID http://orcid.org/0000-0002-7211-6454
Emily LancsarDepartment of Health Economics Wellbeing and Society, National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australia.ORCID http://orcid.org/0000-0003-2404-6735

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fair distribution of limited health funding is a universal challenge for health systems. Decisions about funding new technologies provide a helpful lens on this complex issue. This study examined how two of the world's most mature centralised review processes for health technology funding, namely the Australian Pharmaceutical Benefits and Medical Services Advisory Committees (PBAC and MSAC) have approached fairness over time. Using the Accountability for Reasonableness (A4R) framework, which defines fair priority-setting through four conditions (Relevance, Publicity, Revision, and Enforcement), we conducted (i) a detailed document review of policy changes (2014-2022) and (ii) semi-structured interviews with decision-makers at PBAC and MSAC in 2014 (n = 12) and 2021/22 (n = 11). In both the document review and the interviews, we found increased alignment with A4R principles over time, including enhanced Relevance through increased consumer representation, increased Publicity of decision rationales, and greater Enforcement through broader committee deliberation. However, Revision was not a pressing concern of committee members at either time point despite notable policy changes that improved Revision. Persistent barriers to Publicity were identified, particularly the redaction of decision rationales in public summary documents due to sponsor confidentiality requirements and challenges of explaining nuanced deliberations rather than formulaic criteria. Our findings illustrate how A4R principles are applied in practice and highlight the challenge of balancing procedural fairness with substantive ethical considerations, such as equity and cost effectiveness, that underlie the criterion of Relevance.

Indexed as

Accountability for Reasonableness (A4R)Decision-makingFairnessHealthcareHealth Technology Assessment (HTA)MSACPBACPriority-setting

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.